Cullinan Oncology (CGEM) Investor Presentation - Slideshow

There is a compelling biological and clinical rationale for targeting • 10 mg/kg: 1 ovarian (ongoing after 3 cycles), 1 cervical (ongoing after 6 cycles) 0 10 20 30 0 Stu y Duration ( eeks) MICA-NKG2D Binding in Presence of CLN-619 Abs References 1. Chihara et al. Lancet 2022. 2. Papadopoulos et al. ASCO 2019. 3. Bendell et al. AACR 2020. 4. Patients who underwent at least one RECIST response assessment or who had clinically assessed PD prior to first planned assessment 5. Endometrial, cervical, and ovarian ...